PubMed Health⌕ Search

Biomedical subjects

J C Ridway

Publications and source records attributed to J C Ridway.

At least 19 recordsLinked to original sources
PubMed1994

Acute promyelocytic leukaemia and Hodgkin's disease in the same patient.

Acute non-lymphocytic leukaemia is a well recognised and increasingly reported complication of treated Hodgkin's disease. The prognosis is generally poor with a disappointing response to chemotherapy. A patient in whom myelodysplastic features appeared after treatment for Hodgkin's disease, to be followed shortly afterwards by acute promyelocytic leukaemia, is reported. Complete remission was achieved and sustained until Hodgkin's disease reappeared three years later when the patient was autografted with a marrow harvested four years earlier. The patient remains in good health with platelet support at the time of writing.

Adult↗
PubMed1989

Infectious mononucleosis with acute thrombocytopenia.

Three cases of severe acute thrombocytopenia complicating infectious mononucleosis are described. Although spontaneous remission may be a feature of this rare complication, in each of these cases steroid therapy resulted in a rapid rise in the platelet count.

Adolescent↗
PubMed1989

Lactic dehydrogenase estimation in haematological malignancies.

Earlier studies have indicated a role for serum lactic dehydrogenase (LDH) in haematological and other malignancies. As this is still not a routine test in many units, its value has been re-examined in a retrospective analysis of serum LDH levels in 278 patients with haematological malignancies managed in a single unit. Abnormal levels at diagnosis were found in 42% of these disorders; yet analysis of over 23,000 routine requests for a biochemical screen showed only 4% with an abnormal LDH level. The estimation was also valuable in follow-up of those haematological patients, with rising levels often indicating progressive or relapsing disease even in cases which had shown a normal LDH at diagnosis.

Adult↗
PubMed1988

Expression of human CD4 by two human-mouse interlineage hybrids.

Two hybrid cell lines expressing human CD4 were prepared by fusing human B-lymphoid cells with the mouse T-lymphoma BW5147. Hybrid TF42 was derived from a human B-lymphoblastoid line and TF53.1 from a human B-ALL. Variants of these hybrids expressing or lacking CD4 were isolated by sorting cells stained with the monoclonal antibody (mAb) OKT4 on a fluorescence-activated cell sorter (FACS). Cytogenetic, isoenzyme and DNA analysis confirmed the presence of human chromosome 12 in the CD4+ hybrids, and revealed that CD4 expression by TF42 was associated with multiple copies of this chromosome. Of seventy mAb recognizing human T-cell antigens screened on the CD4+ and CD4- variants of the two hybrids, only mAb recognizing CD4 and Leu 8 reacted with the CD4+ cells. These hybrids should be useful in the preparation, screening and analysis of anti-CD4 monoclonal antibodies, and in studies of CD4 epitopes recognized by HIV.

Animals↗
PubMed1988

Problems of myeloma in a community.

The presenting features of 120 consecutive cases of myeloma diagnosed in a single unit were examined. Screening tests on routine laboratory samples increased the detection rate but did not significantly reduce the percentage of cases presenting with late stage disease. Morbidity was closely related to the incidence of bone involvement already present at diagnosis. About one fifth of cases had reported suspicious symptoms for some considerable time before further investigation was forthcoming. Almost half had 'benefitted' by having concurrent disease which often led to the discovery of myeloma at an early stage. These findings, together with the wide variety of symptomatology and few physical signs, stressed the critical importance of having a high index of suspicion and thus taking suitable blood samples without unnecessary delay.

Aged↗
PubMed1988

The anion gap as a screening procedure for occult myeloma in the elderly.

Myeloma in the elderly can mimic many disorders, causing delay in diagnosis. In a retrospective study, the mean anion gap at presentation in 78 elderly patients with confirmed myeloma was found to be significantly less than that of aged-matched controls. It is suggested that estimation of the anion gap may be useful as a screening test, particularly as it has no intrinsic cost.

Acid-Base Equilibrium↗
PubMed1986

HLA-A,B and DR antigens in chronic lymphocytic leukaemia.

Eighty-three patients with B cell chronic lymphocytic leukaemia were typed for HLA-A,B, and DR antigens. HLA-A2 was found to be significantly increased in patients compared to controls. The frequency of antigens A2,B12(44),DR7 occurring together was more than double the frequency found in the controls. In 48 patients requiring treatment, there was a significant reduction of B8 when compared to 34 untreated patients, and DR7 was significantly increased in frequency in treated patients. Thirty patients presented with sub-clinical symptoms (Rai stage 0). HLA-A10 was significantly more common than in those patients presenting with more advanced disease (Rai stages 1-4). The highest frequency of any HLA antigen was found in males presenting with clinical symptoms, 71.0 per cent of whom were A2 positive; in the same group, 22.6 per cent of patients were positive for all the antigens A2,B12(44),DR7. Patients with an age of onset greater than the mean age of 69 years were more likely to be A2 positive. We conclude that HLA-B8 is a marker of mild disease while HLA-A2 and the closely associated antigens B12(44) and DR7 are markers for severe disease.

Adult↗
PubMed1984

Lack of correlation between lymphocyte activating determinants and HLA-DR on acute leukaemias.

The expression of allogenic lymphocyte-activating determinants (LAD) on 25 acute leukaemias has been compared with the expression of cell-surface antigens identified by HLA-DR allo- and xeno-antisera. The close correlation between LAD and DR known to occur on normal lymphocytes was not found in leukaemias. Twenty-two LAD+ leukaemias included 2 DR- cases, whilst 2 LAD- leukaemias were DR+. With the exception of 3 leukaemias all were strongly beta 2 microglobulin+. No correlation was found between the % DR+ cells and the level of lymphocyte stimulation. Separation of leukaemia cells on Ficoll gradients into fractions containing different proportions of DR+ cells did not correlate with LAD expression. Furthermore, antisera to DR antigens only partially blocked leukaemic LAD. The results support the notion that LAD on acute leukaemias are not necessarily associated with or identical to HLA-DR antigens, and that the lymphocyte activating capacity of HLA-DR may be modulated.

Acute Disease↗
PubMed1979

Fc receptors on myeloid leukaemic cells: comparison between assays of rosette-forming cells.

A comparison has been made between assays of Fc receptor bearing cells among blood leucocytes from normal individuals and from patients with myeloid leukaemia, using human anti-D coated erythrocytes (HEA) and sheep erythrocytes sensitised with a rabbit anti-sheep erythrocyte antibody (SEA). Differences were found between the assays in both groups, demonstrating the heterogeneity of Fc receptors with respect to affinity for marker, and for Fc bearing leucocytes. Monocytoid cells reacted more readily with both markers than myeloid cells. The HEA rosette assay may be useful selective diagnostic aid for Fc+ myeloid leukaemia since the SEA assay detects Fc receptors on mature granulocytes.

Animals↗